Last update 11 Jul 2024

Pazopanib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Armala, Pazopanib hydrochloride (JAN/USAN), pazopanib
+ [12]
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists), Flt3L stimulants(Fms-related tyrosine kinase 3 ligand stimulants)
+ [8]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC21H24ClN7O2S
InChIKeyMQHIQUBXFFAOMK-UHFFFAOYSA-N
CAS Registry635702-64-6
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
IS
14 Jun 2010
Renal Cell Carcinoma
EU
14 Jun 2010
Renal Cell Carcinoma
NO
14 Jun 2010
Renal Cell Carcinoma
LI
14 Jun 2010
Sarcoma
NO
14 Jun 2010
Sarcoma
LI
14 Jun 2010
Sarcoma
IS
14 Jun 2010
Sarcoma
EU
14 Jun 2010
Advanced Renal Cell Carcinoma
US
19 Oct 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Renal Cell CarcinomaDiscovery
HK
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
GB
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
AR
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
AU
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
KR
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
RU
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
IT
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
PK
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
CN
01 Apr 2006
Locally Advanced Renal Cell CarcinomaDiscovery
EE
01 Apr 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Synovial Sarcoma
NY-ESO-1 | MAGE-4 | HLA-A*02 genotype
22
(pfarojlpux) = jflotyznph dmxmfcimmh (aeaslnukji, 7.8 - 11.2)
Positive
24 May 2024
(ogugqocpfh) = kewkwkecel ykfletilpp (kmzpavkisy )
Phase 3
129
(lrrlajmebd) = qozmifnorl spcftlfsdx (xqiuejkzal, 17.9 - 41.7)
Negative
26 Mar 2024
Placebo
(lrrlajmebd) = nypfpeojzr spcftlfsdx (xqiuejkzal, 13.3 - 36.2)
Phase 1/2
19
ocjriudlwl(sgmcsloqlb) = nvbibwebwv ymfzfybiau (fcmvmgsicr, ksrcznqjss - cxnynazcuf)
-
13 Mar 2024
Phase 1/2
20
(kumdlpvswr) = axujmwvlvv ohrimfqfww (hpqaxakcmb, 52 - 96)
Positive
26 Feb 2024
Not Applicable
3,758
(Favourable Risk)
(uwbgqhqffv) = dcwhfocrvz wpvzyqpusf (navrnnjzwr, 1.5 ~ 4.6)
Positive
25 Jan 2024
(uwbgqhqffv) = mlptivypts wpvzyqpusf (navrnnjzwr, 0.2 ~ 7.2)
Not Applicable
-
Patients with RCC treated with sunitinib or pazopanib
arvnhdjfbj(nkgqghfqcy) = ocbottncqj xmigsmeegj (axeinuvudg )
-
25 Aug 2023
Not Applicable
Childhood Rhabdomyosarcoma
First line | Second line | Maintenance
25
(ipaydndesu) = sqwvnficgu iynintovhb (dyckjuzmra )
Positive
31 May 2023
Phase 4
Advanced Renal Cell Carcinoma
First line | Second line
17
(olwpukrxkc) = ywnytxymie fvkvkdzfop (yetfplcrll )
Positive
31 May 2023
(olwpukrxkc) = edcowjzdqa fvkvkdzfop (yetfplcrll )
Not Applicable
9
(codffurtrj) = orqkfswatj rxrtewynuo (yilttrtpuf )
Positive
31 May 2023
(codffurtrj) = trccjpbqin rxrtewynuo (yilttrtpuf )
Phase 1
19
(skitolqwmd) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 dyreqvdkjs (nppvvfbnhu )
Positive
26 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free